Who are Camrelizumab and Cetuximab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/camrelizumab-and-cetuximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Camrelizumab and Cetuximab — Competitive Intelligence Brief

Camrelizumab and Cetuximab (Camrelizumab and Cetuximab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor + EGFR inhibitor combination. Area: Oncology.

phase 3 PD-1 inhibitor + EGFR inhibitor combination PD-1 and EGFR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Camrelizumab and Cetuximab (Camrelizumab and Cetuximab) — Yue He, MD. Camrelizumab blocks PD-1 to enhance immune response while cetuximab blocks EGFR to inhibit tumor cell growth, combining immunotherapy with targeted therapy.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Camrelizumab and Cetuximab TARGET	Camrelizumab and Cetuximab	Yue He, MD	phase 3	PD-1 inhibitor + EGFR inhibitor combination	PD-1 and EGFR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor + EGFR inhibitor combination class)

Yue He, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Camrelizumab and Cetuximab — Competitive Intelligence Brief. https://druglandscape.com/ci/camrelizumab-and-cetuximab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab